Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834766 · ClinicalTrials.gov registry record · Phase 3
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
A Phase 3 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT03834766 is a Phase 3 study that has completed, run by Tris Pharma. The registered enrollment target is 130 participants.
The verdict
NCT03834766, a Phase 3 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
Interventions
- DRUG AMPH ER Tab 5, 10, 15 and 20 mg
- DRUG AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2019-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834766
The ClinicalTrials.gov registry entry for NCT03834766 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMPH ER Tab 5, 10, 15 and 20 mg is the first listed.
NCT03834766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03834766 about?
NCT03834766 is a clinical study titled "Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD". To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
What is the current status of trial NCT03834766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2019-02-06. Estimated completion is 2019-10-19.
What interventions are being tested in trial NCT03834766?
The interventions under investigation include: AMPH ER Tab 5, 10, 15 and 20 mg (DRUG), AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg (DRUG).
Who is sponsoring clinical trial NCT03834766?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.